follow recent earn report publish revis model
updat forecast onvo
hold high expect nearli straight yr post signific
quarterli upsid organ growth lc basic right line
expect result modest ep beat also re-affirmed organ
growth guidanc lc impli normal clip
past two yr lap tougher comp particularli china seem like
moder msd/hsd tailwind pent-up industri demand fade on-going
field turbo invest offset raw materi cost inflat could two sourc
potenti revenu upsid step back end-market fundament
favor execut remain best-in-class stock alreadi seem discount high
expect upsid number valuat premium absolut
ebitda rel base prem vs three-yr average keep us hold
model adjust rais ep
respect pt unchang impli ev ufcf
hold great momentum guid lack upsid leverag
robust demand consum genom clinic genet test market
clearli evid rev surg y/i crush expect
upsid howev think stock trade lower sinc print due lack
upsid revenue guidanc line consensu commentari
call led question whether strength one-tim weak
product fell y/i despit contribut higher-margin dnag
unit expect guid new ceo come on-board
think reluct set higher bar step back continu
like way get exposur consum genom market cautiou
deceler product revenue growth vs stem egypt
hcv contract loss tough comp could weigh multipl
model adjust rais rev
respect account upsid higher est ancestrydna royalti
kick vs prior pt base
sotp includ dnag rev line high growth comp
onvo buy revenu ramp remain elus core product servic rev
miss howev guidanc reduct concern onvo
cut revenue outlook second quarter row lower high-end
inher lumpi project start low visibl around contract time
continu frustrat abil forecast busi onvo point sever sign
posit commerci progress new acct new ytd order ytd
repeat/new samsara rev y/i abil convert interest revenu
slow onvo on-going util atm facil even low
 yr cash runway somewhat concern us investor
wait anoth quarter sign revenu inflect still think platform
inher valu seen novel emerg platform tech pharma
adopt curv could turn lower slower model adj lower rev
 respect pt unchang
pleas see analyst certif import disclosur inform inform regard statu non-u analyst page report
million except per share data
page
pleas see import disclosur inform page report
prior yearforecastreportedactualpercentactualpercentepsnet product incom share share analysisgross research sg oper incom incom net healthcar
million except per share data
page
pleas see import disclosur inform page report
earn per flow cash cash flow cash flow per cash net interest free cash stock-bas sheet metricsreceiv day day day convers interest debt ttm debt ttm valu per
histor project quarterli incom statement
million except per share data
page
pleas see import disclosur inform page report
histor total net product incom share share analysisgross sg oper incom net growth analysisnet gross sg oper net dilut healthcar
million except per share data
page
pleas see import disclosur inform page report
vs growthv expectationsprior yearforecastreportedactualpercentactualpercentepsnet product administr expens share share analysiscorpor gross gross administr healthcar
million except per share
page
pleas see import disclosur inform page report
histor earn per flow cash cash flow cash flow per cash sheet metricsreceiv day day day convers interest debt ttm debt ttm valu per
histor project quarterli incom statement
million except per share
page
pleas see import disclosur inform page report
histor total net product administr expens share ep analysiscorpor gross product gross research sale gener administr oper incom net growth analysisnet gross research sale gener administr net dilut
onvo histor project quarterli incom statement
million except per share
page
pleas see import disclosur inform page report
